Expression of Transcription Factor PU.1 in Stromal Cells as a Prognostic Marker in Non-Small Cell Lung Cancer

Ковалева, О. В.; Рашидова, М. А.; Samoilova, Daria V.; Podlesnaya, P. A.; Мочальникова, В В; Gratchev, Alexei

doi:10.1007/s10517-021-05094-7

Cited by 2 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Association of its expression with progression of the disease and an unfavorable prognosis were established for both tumor types. PU.1 expression has also been studied in non-small cell lung cancer (NSCLC) [ 13 ], colorectal cancer [ 14 ], and esophageal cancer [ 10 ]. One study was devoted to the study of PU.1 expression in GC, which showed that PU.1 expression is significantly elevated in gastric tumor tissue compared to the relative norm and is associated with an unfavorable prognosis and disease progression.…”

Section: Discussionmentioning

confidence: 99%

“…В контексте солидных опухолей изучена клиническая значимость экспрессии PU.1 у больных раком молочной железы и глиомами [11,12], причем показана ассоциация его экспрессии с прогрессией и неблагоприятным прогнозом при обеих нозологиях. Экспрессия PU.1 изучена также при немелкоклеточном раке легкого (НМРЛ) [13], раке толстой кишки [14] и пищевода [10]. Изучению экспрессии PU.1 при РЖ посвящено одно исследование, в котором показано, что экспрессия PU.1 значительно повышена в опухолевой ткани желудка по сравнению с относительной нормой и ассоциирована с неблагоприятным прогнозом и прогрессированием заболевания.…”

Section: Discussionunclassified

See 1 more Smart Citation

Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer

et al. 2023

View full text Add to dashboard Cite

A comprehensive analysis of the cell phenotype of the inflammatory infiltrate of the tumor stroma represents a promising area of molecular oncology. The study of not only soluble forms of various immunoregulatory molecules, but also their membrane-bound forms is also considered highly relevant. We performed a comprehensive analysis of tissue and circulating forms of the PD-1 and PD-L1 proteins, as well as macrophage and B-cell markers in the tumor stroma of gastric cancer, to assess their clinical and prognostic significance. The tumor and blood plasma samples from 63 gastric cancer patients were studied using ELISA and immunohistochemistry. Malignant gastric tumors were shown to be strongly infiltrated by B-cells, and their number was comparable to that of macrophages. For PU.1 expression, an association with tumor size was observed; i.e., larger tumors were characterized by fewer PU.1+ infiltrating cells (p = 0.005). No clinical significance was found for CD20 and CD163, but their numbers were higher at earlier stages of the disease and in the absence of metastases. It was also demonstrated that the PD-L1 content in tumor cells was not associated with the clinical and morphological characteristics of GC. At the same time, PD-L1 expression in tumor stromal cells was associated with the presence of distant metastases. The analysis of the prognostic significance of all the markers studied demonstrated that CD163 was statistically significantly associated with a poor prognosis for the disease (p = 0.019). In addition, PD-L1 expression in tumor cells tended to indicate a favorable prognosis (p = 0.122). The results obtained in this work indicate that the study of soluble and tissue markers of tumor stroma is promising in prognosticating the course of GC. The search for combinations of markers seems to be highly promising, with their comprehensive analysis capable of helping personalize advanced antitumor therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionunclassified

Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The regulatory effects of SPI1 on BTN3A1 were confirmed by our ‘wet’ experiments. The expression of SPI1 in NSCLCs has been reported, and increased number of PU.1+ cells is correlated with favorable prognosis of adenocarcinoma and poor prognosis of squamous cell carcinoma [35]. PU.1 is also a major transcriptional activator of the tumor suppressor gene LIMD1 [36].…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models

et al. 2021

View full text Add to dashboard Cite

Butyrophilin 3A1 (BTN3A1), a major histocompatibility complex (MHC)-associated gene that encodes a membrane protein with 2 extracellular immunoglobulin domains and an intracellular B30.2 domain, is critical in T-cell activation and adaptive immune response. Here, the expression of BTN3A1 in cancers was analyzed in 8 databases comprising 86,733 patients of 33 cancers and the findings were validated in patient samples and cell models. We showed that BTN3A1 was expressed in most cancers, and its expression level was strongly correlated with clinical outcome of 13 cancers. Mutations of BTN3A1 were detected, and the mutations were distributed throughout the entire gene. Gene set enrichment analysis (GSEA) showed that BTN3A1 co-expression genes and interacting proteins were enriched in immune regulation related pathways. BTN3A1 was associated with tumor infiltrating immune cells and was co-expressed with multiple immune checkpoints in patients with breast cancer (BRCA) and non-small cell lung cancer (NSCLC). We reported that BTN3A1 was downregulated in 46 of 65 (70.8%) NSCLCs, and its expression level was inversely associated with clinical outcome of the patients. BTN3A1 in tumor samples was lower than in counterpart normal tissues in 31 of 38 (81.6%) BRCAs. Bioinformatics analyses showed that BTN3A1 could be a target gene of transcription factor Spi-1 proto-oncogene (SPI1), and our "wet" experiments showed that ectopic expression of SPI1 upregulated, whereas silencing of SPI1 downregulated, BTN3A1 expression in cells. These results suggest that

show abstract

Expression of Transcription Factor PU.1 in Stromal Cells as a Prognostic Marker in Non-Small Cell Lung Cancer

Cited by 2 publications

References 8 publications

Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer

Comprehensive Analysis of Stromal and Serum Markers in Gastric Cancer

Comprehensive analysis of BTN3A1 in cancers: mining of omics data and validation in patient samples and cellular models

Contact Info

Product

Resources

About